ORKA · NASDAQ · STOCK
Oruka Therapeutics (ORKA) Stock Analysis
$82.17
52W $24.46 – $115.52
53/100
$4.95B
-33.2
-0.39
Is ORKA Bullish or Bearish?
Mixed.
Innellis AI committee rates Oruka Therapeutics, Inc. (ORKA) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.08 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.92 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -20.8% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 28.6% signals elevated volatility — Risk
- No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 80%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -20.8% -- cheap may mean cheap for a reason
Growth Analyst
bearish
35
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 28.6% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.2 to 52.9.
- Committee agreement increased notably from 33% to 50%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
43.7
Neutral
MACD Histogram
-0.472
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$53.85
Resistance
$90.61
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$82.20
Below
EMA 21
$86.05
Below
EMA 50
$89.00
Below
EMA 200
$69.57
Above
Fundamental Analysis
Valuation
84
Growth
59
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-33.2×
P/B Ratio
4.63×
PEG Ratio
-0.61
Dividend Yield
0.00%
52W High
$115.52
52W Low
$24.46
Quality & Growth
ROE
-2234.1%
ROA
-2157.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -33.2 (inexpensive relative to a 15-40x range); Price-to-book of 4.6x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -22.3%; Return on assets of -21.6%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 38.51 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-1.61); Most recent quarter missed estimates by 4.6%; EPS growth decelerating (-6.7% -> -14.6% QoQ); Analyst estimates rising over recent quarters
Get the Full ORKA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →